{"id":45738,"date":"2024-02-05T08:00:18","date_gmt":"2024-02-05T08:00:18","guid":{"rendered":"https:\/?p=45738"},"modified":"2024-02-05T08:00:18","modified_gmt":"2024-02-05T08:00:18","slug":"eli-lillys-fourth-quarter-earnings-report","status":"publish","type":"post","link":"https:\/\/www.stocktargetadvisor.com\/blog\/eli-lillys-fourth-quarter-earnings-report\/","title":{"rendered":"Eli Lilly&#8217;s Fourth-Quarter Earnings Report: What to Expect"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">Eli Lilly and Company (<\/span><a href=\"https:\/\/www.stocktargetadvisor.com\/stock\/USA\/NYE\/LLY\"><span style=\"font-weight: 400;\">LLY: NYE<\/span><\/a><span style=\"font-weight: 400;\">) is due to release its fourth-quarter earnings report this week. As investors eagerly await the update, industry experts offer their insights on what to expect from the company&#8217;s financial performance.<\/span><\/p>\n<p>&nbsp;<\/p>\n<h2><strong>Eli Lilly&#8217;s Growth Prospects: J.P. Morgan Analysis Reveals<\/strong><\/h2>\n<p><span style=\"font-weight: 400;\">Leading analyst Chris Schott from J.P. Morgan has underscored growth prospects for Eli Lilly deriving from the success of Mounjaro and the potential of donanemab, a pioneering treatment set for launch in 2025. Schott&#8217;s estimate for fourth-quarter revenue is $8.97 billion, attributing significant revenue contribution to Mounjaro. Nonetheless, Zepbound sales are predicted to be moderate.<\/span><\/p>\n<p><!-- STA Widget BEGIN --><\/p>\n<div>\n<div class=\"sta-analyst-rating-widget-display\">\n<p><a style=\"text-decoration: none; color: #4b6db5 !important;\" href=\"https:\/\/www.stocktargetadvisor.com\/stock\/USA\/NYE\/LLY\" target=\"_blank\" rel=\"noopener\">LLY Ratings<\/a> by Stock Target Advisor<\/p>\n<\/div>\n<p><script class=\"analyst-rating\" type=\"text\/javascript\" src=\"https:\/\/www.stocktargetadvisor.com\/assets\/js\/analyst_rating_widget.js\" data-symbol=\"LLY\" data-theme=\"wt_bg_trans\" data-uid=\"209282074465c094d52b9ff65c094d52ba00\" data-width=\"700\" >\n\t\t<\/script><\/p>\n<\/div>\n<p><span style=\"font-weight: 400;\">Looking to the future, Eli Lilly&#8217;s revenue growth for 2024 is projected by Schott at 16% year-over-year with the company&#8217;s incretin franchise forecasted to achieve $50 billion by 2030.<\/span><\/p>\n<p>&nbsp;<\/p>\n<h2><strong>Stock Target Advisor&#8217;s Analysis on Eli Lilly:<\/strong><\/h2>\n<p><span style=\"font-weight: 400;\"><a href=\"https:\/\/www.stocktargetadvisor.com\/\">Stock Target Advisor<\/a> maintains a &#8216;Hold&#8217; stance on Eli Lilly&#8217;s stock with a target price of 0 and envisions no price change over a 12-month period. However, the average analyst target price for Eli Lilly over the next year stands at $631.37 with a consensus rating of &#8216;Strong Buy.&#8217; When it comes to Stock Target Advisor&#8217;s analysis, the view is Neutral, backed by 9 positive signals against 10 negative signals.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The company&#8217;s stock price has witnessed a surge of +28.40% over the preceding week, +53.15% over the last month, and +96.90% over the past year. These developments denote superior risk-adjusted returns and positive cash flow for Eli Lilly.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The <a href=\"https:\/\/www.stocktargetadvisor.com\/screens\/industries\/Drug%20Manufacturers%20-%20Major\">Drug Manufacturers<\/a> &#8211; General sector, inclusive of Eli Lilly, has been rated as &#8216;Neutral&#8217; by Stock Target Advisor with average returns of -1.14% spanning a month.<\/span><\/p>\n<p>&nbsp;<\/p>\n<h2><strong>Conclusion:<\/strong><\/h2>\n<p><span style=\"font-weight: 400;\">Eli Lilly&#8217;s forthcoming earnings report carries the potential to steer the company&#8217;s trajectory in 2024. Investors are encouraged to closely keep tabs on the company&#8217;s financial performance and the resulting impact of key products on its revenue and profitability.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eli Lilly and Company (LLY: NYE) is due to release its fourth-quarter earnings report this week. As investors eagerly await the update, industry experts offer&#8230;<\/p>\n","protected":false},"author":17,"featured_media":41144,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-45738","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v19.4 (Yoast SEO v21.4) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Eli Lilly&#039;s Fourth-Quarter Earnings Report: What to Expect<\/title>\n<meta name=\"description\" content=\"Discover what analysts expect from Eli Lilly&#039;s 4Q earnings report and the growth prospects for the coming years. Is it time to invest?\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.stocktargetadvisor.com\/blog\/eli-lillys-fourth-quarter-earnings-report\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly&#039;s Fourth-Quarter Earnings Report: What to Expect\" \/>\n<meta property=\"og:description\" content=\"Discover what analysts expect from Eli Lilly&#039;s 4Q earnings report and the growth prospects for the coming years. Is it time to invest?\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/eli-lillys-fourth-quarter-earnings-report\/\" \/>\n<meta property=\"og:site_name\" content=\"Stock Target Advisor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-02-05T08:00:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2023\/10\/eli-lilly.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Muzzammil Ahmad\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@https:\/\/x.com\/Muzzammil625\" \/>\n<meta name=\"twitter:site\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Muzzammil Ahmad\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/eli-lillys-fourth-quarter-earnings-report\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/eli-lillys-fourth-quarter-earnings-report\/\"},\"author\":{\"name\":\"Muzzammil Ahmad\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8\"},\"headline\":\"Eli Lilly&#8217;s Fourth-Quarter Earnings Report: What to Expect\",\"datePublished\":\"2024-02-05T08:00:18+00:00\",\"dateModified\":\"2024-02-05T08:00:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/eli-lillys-fourth-quarter-earnings-report\/\"},\"wordCount\":316,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"articleSection\":[\"Market News &amp; Insights\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/eli-lillys-fourth-quarter-earnings-report\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/eli-lillys-fourth-quarter-earnings-report\/\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/eli-lillys-fourth-quarter-earnings-report\/\",\"name\":\"Eli Lilly's Fourth-Quarter Earnings Report: What to Expect\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\"},\"datePublished\":\"2024-02-05T08:00:18+00:00\",\"dateModified\":\"2024-02-05T08:00:18+00:00\",\"description\":\"Discover what analysts expect from Eli Lilly's 4Q earnings report and the growth prospects for the coming years. Is it time to invest?\",\"breadcrumb\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/eli-lillys-fourth-quarter-earnings-report\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/eli-lillys-fourth-quarter-earnings-report\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/eli-lillys-fourth-quarter-earnings-report\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly&#8217;s Fourth-Quarter Earnings Report: What to Expect\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"name\":\"Stock Target Advisor\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\",\"name\":\"Stock Target Advisor\",\"alternateName\":\"STA\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"contentUrl\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"width\":\"225\",\"height\":\"225\",\"caption\":\"Stock Target Advisor\"},\"image\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\",\"https:\/\/twitter.com\/AdvisorTarget\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8\",\"name\":\"Muzzammil Ahmad\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g\",\"caption\":\"Muzzammil Ahmad\"},\"description\":\"Muzzammil is a content writer at Stock Target Advisor. He has been writing stock news and analysis at Stock Target Advisor since 2023 and has worked in the financial domain in various roles since 2020. He has previously worked on an equity research firm that analyzed companies listed on the stock markets in the U.S. and Canada and performed fundamental and qualitative analyses of management strength, business strategy, and product\/services forecast as indicated by major brokers covering the stock.\",\"sameAs\":[\"https:\/\/www.linkedin.com\/in\/muzzammil-ahmad-a157b1190\/\",\"https:\/\/twitter.com\/https:\/\/x.com\/Muzzammil625\"],\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/author\/muzzammil\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli Lilly's Fourth-Quarter Earnings Report: What to Expect","description":"Discover what analysts expect from Eli Lilly's 4Q earnings report and the growth prospects for the coming years. Is it time to invest?","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.stocktargetadvisor.com\/blog\/eli-lillys-fourth-quarter-earnings-report\/","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly's Fourth-Quarter Earnings Report: What to Expect","og_description":"Discover what analysts expect from Eli Lilly's 4Q earnings report and the growth prospects for the coming years. Is it time to invest?","og_url":"https:\/\/www.stocktargetadvisor.com\/blog\/eli-lillys-fourth-quarter-earnings-report\/","og_site_name":"Stock Target Advisor","article_publisher":"https:\/\/www.facebook.com\/StockTargetAdvisor\/","article_published_time":"2024-02-05T08:00:18+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2023\/10\/eli-lilly.png","type":"image\/png"}],"author":"Muzzammil Ahmad","twitter_card":"summary_large_image","twitter_creator":"@https:\/\/x.com\/Muzzammil625","twitter_site":"@AdvisorTarget","twitter_misc":{"Written by":"Muzzammil Ahmad","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/eli-lillys-fourth-quarter-earnings-report\/#article","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/eli-lillys-fourth-quarter-earnings-report\/"},"author":{"name":"Muzzammil Ahmad","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8"},"headline":"Eli Lilly&#8217;s Fourth-Quarter Earnings Report: What to Expect","datePublished":"2024-02-05T08:00:18+00:00","dateModified":"2024-02-05T08:00:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/eli-lillys-fourth-quarter-earnings-report\/"},"wordCount":316,"commentCount":0,"publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"articleSection":["Market News &amp; Insights"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.stocktargetadvisor.com\/blog\/eli-lillys-fourth-quarter-earnings-report\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/eli-lillys-fourth-quarter-earnings-report\/","url":"https:\/\/www.stocktargetadvisor.com\/blog\/eli-lillys-fourth-quarter-earnings-report\/","name":"Eli Lilly's Fourth-Quarter Earnings Report: What to Expect","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website"},"datePublished":"2024-02-05T08:00:18+00:00","dateModified":"2024-02-05T08:00:18+00:00","description":"Discover what analysts expect from Eli Lilly's 4Q earnings report and the growth prospects for the coming years. Is it time to invest?","breadcrumb":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/eli-lillys-fourth-quarter-earnings-report\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.stocktargetadvisor.com\/blog\/eli-lillys-fourth-quarter-earnings-report\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/eli-lillys-fourth-quarter-earnings-report\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.stocktargetadvisor.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly&#8217;s Fourth-Quarter Earnings Report: What to Expect"}]},{"@type":"WebSite","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","name":"Stock Target Advisor","description":"","publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization","name":"Stock Target Advisor","alternateName":"STA","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/","url":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","contentUrl":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","width":"225","height":"225","caption":"Stock Target Advisor"},"image":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/StockTargetAdvisor\/","https:\/\/twitter.com\/AdvisorTarget"]},{"@type":"Person","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8","name":"Muzzammil Ahmad","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g","caption":"Muzzammil Ahmad"},"description":"Muzzammil is a content writer at Stock Target Advisor. He has been writing stock news and analysis at Stock Target Advisor since 2023 and has worked in the financial domain in various roles since 2020. He has previously worked on an equity research firm that analyzed companies listed on the stock markets in the U.S. and Canada and performed fundamental and qualitative analyses of management strength, business strategy, and product\/services forecast as indicated by major brokers covering the stock.","sameAs":["https:\/\/www.linkedin.com\/in\/muzzammil-ahmad-a157b1190\/","https:\/\/twitter.com\/https:\/\/x.com\/Muzzammil625"],"url":"https:\/\/www.stocktargetadvisor.com\/blog\/author\/muzzammil\/"}]}},"_links":{"self":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/45738","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/users\/17"}],"replies":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/comments?post=45738"}],"version-history":[{"count":1,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/45738\/revisions"}],"predecessor-version":[{"id":45740,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/45738\/revisions\/45740"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media\/41144"}],"wp:attachment":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media?parent=45738"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/categories?post=45738"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/tags?post=45738"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}